Division of Hematology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD, USA.
Haematologica. 2010 Jul;95(7):1090-7. doi: 10.3324/haematol.2009.014407. Epub 2010 Feb 4.
The JAK2(V617F) allele burden is a variable measure, determined by the frequency of mitotic recombination events and the expansion of JAK2(V617F) clones. Since variability in the JAK2(V617F) allele burden is partly responsible for the distinct phenotypes seen in the myeloproliferative disorders, the objective of this study was to identify modifiers of the allele burden.
Blood samples were obtained between May 2005 and January 2009 from 272 patients with essential thrombocytosis, polycythemia vera, and myelofibrosis. The JAK2(V617F) allele burden was measured by an allele-specific quantitative polymerase chain reaction using DNA from purified neutrophils. Repeated measures, on average 2 years apart, were available for 104 patients.
Sex, age at diagnosis, and disease duration all independently influenced the JAK2(V617F) allele burden. When considering all patients with myeloproliferative disorders, women had significantly lower allele burdens than men (P=0.04). In those patients with repeated measures, the increase in allele burden per year between the first and second evaluations was significantly less in females than in males. Among those who experienced disease evolution, females were 4.5 times more likely to have evolution from essential thrombocytosis to polycythemia vera, but 0.23 times as likely to have evolution from essential thrombocytosis to myelofibrosis.
Sex is an independent factor accounting for variability in the JAK2(V617F) allele burden. We speculate that lower allele burdens in females reflect a lower frequency of mitotic recombination events in females than in males, and should be considered when evaluating the relationship of allele burden to disease phenotype and also in evaluating responses to JAK2(V617F)-inhibitors. Because sex may influence genotype and/or clonal expansion, underpinning the variability in JAK2(V617F) allele burden, it will be important to explore factors that determine susceptibility to mitotic recombination events.
JAK2(V617F)等位基因负担是一个可变的指标,由有丝分裂重组事件的频率和 JAK2(V617F)克隆的扩增决定。由于 JAK2(V617F)等位基因负担的变异性部分解释了骨髓增生性疾病中不同表型的存在,本研究的目的是确定等位基因负担的修饰因子。
本研究于 2005 年 5 月至 2009 年 1 月期间,从 272 名原发性血小板增多症、真性红细胞增多症和骨髓纤维化患者中采集了血液样本。使用从纯化的中性粒细胞中提取的 DNA,通过等位基因特异性定量聚合酶链反应来测量 JAK2(V617F)等位基因负担。对 104 名患者进行了平均 2 年的重复测量。
性别、诊断时的年龄和疾病持续时间均独立影响 JAK2(V617F)等位基因负担。在考虑所有骨髓增生性疾病患者时,女性的等位基因负担明显低于男性(P=0.04)。在那些有重复测量的患者中,第一次和第二次评估之间,每年等位基因负担的增加在女性中明显低于男性。在那些经历疾病进展的患者中,女性从原发性血小板增多症进展为真性红细胞增多症的可能性是男性的 4.5 倍,但从原发性血小板增多症进展为骨髓纤维化的可能性是男性的 0.23 倍。
性别是导致 JAK2(V617F)等位基因负担变异性的独立因素。我们推测,女性的等位基因负担较低反映了女性的有丝分裂重组事件频率低于男性,在评估等位基因负担与疾病表型的关系时应考虑这一点,在评估 JAK2(V617F)抑制剂的反应时也应考虑这一点。由于性别可能影响基因型和/或克隆扩增,从而影响 JAK2(V617F)等位基因负担的变异性,因此,探讨决定有丝分裂重组事件易感性的因素将非常重要。